QHerit™ 381 Diseases, Male
Use
This male carrier screening panel enables molecular detection via next-generation sequencing (NGS) of variants associated with specified autosomal recessive (and X‑linked, as indicated in mirrored female panel descriptions) disorders, allowing carrier screening of individuals regardless of ancestry or geographic origin. It is intended to identify couples at increased risk for having an affected child to facilitate informed reproductive decision‑making. This screening panel is not diagnostic and should not be used as the sole basis for diagnostic or treatment decisions; genetic counseling is recommended if diagnostic testing is desired. The female counterpart is QHerit™ 421 Diseases, Female.
Special Instructions
Not provided.
Limitations
This is a screening test and not intended for diagnostic purposes; results should be interpreted in the context of available clinical findings and genetic counseling should be offered. The test was developed and validated in a CLIA‑certified laboratory; FDA does not require premarket review, and performance is determined internally. The panel may not include all X‑linked conditions depending on gender. Sample exposure to heat may lead to rejection.
Methodology
NGS
Biomarkers
Result Turnaround Time
16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
2 mL
Container
EDTA (lavender‑top) tube
Causes for Rejection
Sample exposed to heat
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant